200,000+ products from a single source!
sales@angenechem.com
Home > Imidazoles > 80621-81-4
80621-81-4 | 2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione,25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-,(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-
CAS No: 80621-81-4 Catalog No: AG00ILMS MDL No:MFCD00864973
Product Description
Catalog Number:
AG00ILMS
Chemical Name:
2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione,25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-,(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-
CAS Number:
80621-81-4
Molecular Formula:
C43H51N3O11
Molecular Weight:
785.8785
MDL Number:
MFCD00864973
IUPAC Name:
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] acetate
InChI:
InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1
InChI Key:
NZCRJKRKKOLAOJ-XRCRFVBUSA-N
SMILES:
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C2=O)c2c(c(c3C)O)c(O)c(c3c2nc2n3ccc(c2)C)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(=O)C)C)O)C)O)C)/C
EC Number:
617-130-4
UNII:
L36O5T016N
Properties
Complexity:
1590
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
9
Defined Bond Stereocenter Count:
3
Exact Mass:
785.352g/mol
Formal Charge:
0
Heavy Atom Count:
57
Hydrogen Bond Acceptor Count:
12
Hydrogen Bond Donor Count:
5
Isotope Atom Count:
0
Molecular Weight:
785.891g/mol
Monoisotopic Mass:
785.352g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
198A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
6.9
Literature
| Title | Journal |
|---|---|
| New brominated flame retardants and their metabolites as activators of the pregnane X receptor. | Toxicology letters 20160930 |
| Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. | Expert opinion on pharmacotherapy 20150101 |
| Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. | The American journal of gastroenterology 20121001 |
| Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice. | Toxicological sciences : an official journal of the Society of Toxicology 20121001 |
| Rifaximin may have a dramatic effect on hepatic encephalopathy. | Clinical medicine (London, England) 20121001 |
| 'Pre-cebo': an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials. | Journal of clinical gastroenterology 20120901 |
| The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. | Journal of clinical gastroenterology 20120901 |
| [Proton-pump inhibitor therapy and small bowel bacterial contamination]. | Orvosi hetilap 20120819 |
| Fitness and molecular mechanisms of resistance to rifaximin in in vitro selected Escherichia coli mutants. | Microbial drug resistance (Larchmont, N.Y.) 20120801 |
| Effects of rifaximin on bacterial translocation in thioacetamide-induced liver injury in rats. | Inflammation 20120801 |
| Fidaxomicin inhibits spore production in Clostridium difficile. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120801 |
| Determination of rifaximin in rat serum by ionic liquid based dispersive liquid-liquid microextraction combined with RP-HPLC. | Journal of separation science 20120801 |
| [Hepatic encephalopathy]. | Deutsche medizinische Wochenschrift (1946) 20120801 |
| Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20120701 |
| High-resolution melting analysis of the single nucleotide polymorphism hot-spot region in the rpoB gene as an indicator of reduced susceptibility to rifaximin in Clostridium difficile. | Journal of medical microbiology 20120601 |
| Pregnane X receptor as a target for treatment of inflammatory bowel disorders. | Trends in pharmacological sciences 20120601 |
| Rifaximin and lubiprostone: the best options for treating irritable bowel syndrome? | Expert review of gastroenterology & hepatology 20120601 |
| [Variation of intestinal fermentative profile after sequential therapy with rifaximin/probiotics]. | Acta gastroenterologica Latinoamericana 20120601 |
| Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats. | World journal of gastroenterology 20120507 |
| Hepatic encephalopathy. | Clinics in liver disease 20120501 |
| Structural elucation of a novel impurity in rifaximin. | Die Pharmazie 20120501 |
| Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. | Hepatology (Baltimore, Md.) 20120401 |
| Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. | Journal of hepatology 20120401 |
| Probable rifaximin-induced neutropenia. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120401 |
| Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. | The American journal of medicine 20120401 |
| [Hepatic encephalopathy and liver transplantation]. | Magyar sebeszet 20120401 |
| Impurity profile of rifaximin produced in China. | Die Pharmazie 20120401 |
| Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. | Scandinavian journal of infectious diseases 20120301 |
| Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. | Liver international : official journal of the International Association for the Study of the Liver 20120301 |
| Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. | Gastroenterology 20120301 |
| The diagnosis and treatment of minimal hepatic encephalopathy. | Deutsches Arzteblatt international 20120301 |
| Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. | World journal of gastroenterology 20120227 |
| Durability of rifaximin response in hepatic encephalopathy. | Journal of clinical gastroenterology 20120201 |
| Rifaximin for the treatment of irritable bowel syndrome. | Expert opinion on pharmacotherapy 20120201 |
| Management of overt hepatic encephalopathy. | Clinics in liver disease 20120201 |
| Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei. | Journal of medicinal chemistry 20120112 |
| Linkage of gut microbiome with cognition in hepatic encephalopathy. | American journal of physiology. Gastrointestinal and liver physiology 20120101 |
| The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. | The American journal of gastroenterology 20120101 |
| [Treatment of recurrent Clostridium difficile diarrhoea using sequential therapy with vancomycin followed by rifaximin]. | Revista espanola de geriatria y gerontologia 20120101 |
| [Diagnostics and treatment of hepatic encephalopathy]. | Deutsche medizinische Wochenschrift (1946) 20120101 |
| Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. | PloS one 20120101 |
| [Role of rifaximin in the treatment of colonic diverticular disease]. | La Clinica terapeutica 20120101 |
| Ammonia abolishers: antibiotics for hepatic encephalopathy. | Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses 20120101 |
| Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis. | Systematic reviews 20120101 |
| A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. | The Journal of antimicrobial chemotherapy 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| [Rifaximin for hepatic encephalopathy in children. Case report]. | Archivos argentinos de pediatria 20111201 |
| Pharmacological treatment of abdominal pain related functional gastrointestinal disorders. | Journal of pediatric gastroenterology and nutrition 20111201 |
| In vitro activity of rifaximin against Chlamydia suis. | The Veterinary record 20111126 |
| Rifaximin in the treatment of inflammatory bowel disease. | World journal of gastroenterology 20111114 |
| Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. | Digestive diseases and sciences 20111101 |
| Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome. | Internal and emergency medicine 20111001 |
| Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. | Digestive diseases and sciences 20111001 |
| Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. | European journal of pharmacology 20111001 |
| Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. | Alimentary pharmacology & therapeutics 20111001 |
| Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. | Diseases of the colon and rectum 20111001 |
| Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile. | Journal of medical microbiology 20110801 |
| The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. | Expert review of gastroenterology & hepatology 20110801 |
| Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin. | The Canadian journal of urology 20110801 |
| Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. | Journal of medicinal chemistry 20110714 |
| Antibiotic prophylaxis prevents the development of a post-infectious phenotype in a new rat model of post-infectious IBS. | Digestive diseases and sciences 20110701 |
| Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. | Digestive diseases and sciences 20110701 |
| A new use for Xifaxan. | The Nurse practitioner 20110701 |
| Rifaximin: new therapeutic indication and future directions. | Clinical therapeutics 20110701 |
| Is bacterial DNA a better marker than endotoxin of bacterial translocation in decompensated cirrhosis? | Hepatology (Baltimore, Md.) 20110601 |
| Antibiotic treatment may ease symptoms of irritable bowel syndrome. | Mayo Clinic women's healthsource 20110601 |
| Small intestinal bacterial overgrowth and Helicobacter pylori: can they be cause of thrombocytopenia in patients with chronic liver disease? | The American journal of gastroenterology 20110601 |
| Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. | Journal of Korean medical science 20110601 |
| Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. | Annals of hepatology 20110601 |
| Comment on: Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. | The Journal of antimicrobial chemotherapy 20110501 |
| Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth. | The Annals of pharmacotherapy 20110501 |
| Rifaximin for irritable bowel syndrome without constipation. | The New England journal of medicine 20110414 |
| Rifaximin for irritable bowel syndrome without constipation. | The New England journal of medicine 20110414 |
| Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain. | Journal of pediatric gastroenterology and nutrition 20110401 |
| Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. | Alimentary pharmacology & therapeutics 20110401 |
| Small intestinal bacterial overgrowth in patients with lower gastrointestinal symptoms and a history of previous abdominal surgery. | Archives of surgery (Chicago, Ill. : 1960) 20110401 |
| Treatment of hepatic encephalopathy with rifaximin: more to think about. | Hepatology (Baltimore, Md.) 20110301 |
| Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. | Gastroenterology 20110201 |
| Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). | The American journal of gastroenterology 20110201 |
| [Rifaximin--a non-resorbable antibiotic with many indications in gastroenterology]. | Zeitschrift fur Gastroenterologie 20110201 |
| Biologic properties and clinical uses of rifaximin. | Expert opinion on pharmacotherapy 20110201 |
| Editorial: rifaximin and minimal hepatic encephalopathy. | The American journal of gastroenterology 20110201 |
| Solomonsterols A and B from Theonella swinhoei. The first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity. | Journal of medicinal chemistry 20110113 |
| Rifaximin therapy for patients with irritable bowel syndrome without constipation. | The New England journal of medicine 20110106 |
| Antibiotic therapy for the irritable bowel syndrome. | The New England journal of medicine 20110106 |
| Identification of clinically used drugs that activate pregnane X receptors. | Drug metabolism and disposition: the biological fate of chemicals 20110101 |
| Rifaximin intake leads to emergence of rifampin-resistant staphylococci. | The Journal of infection 20110101 |
| [Rifaximin in combined treatment of the Helicobacter pylori infection in childhood]. | Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20110101 |
| [Rifaximin application in the overgrowth bacterial syndrome in the small intestine in patients after cholecystectomy]. | Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20110101 |
| A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season. | Journal of travel medicine 20110101 |
| [Optimization of treatment of patients with chronic cardiac insufficiency of the ischemic genesis and hobnail liver]. | Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20110101 |
| [Efficacy of rifaximine in small intestinal bacterial overgrowth syndrome in patients after cholecystectomy]. | Terapevticheskii arkhiv 20110101 |
| Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. | Biochemical pharmacology 20101201 |
| Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. | The Journal of antimicrobial chemotherapy 20101201 |
| Rifaximin for the treatment of hepatic encephalopathy. | Expert review of gastroenterology & hepatology 20101201 |
| Thrombocytopenia associated with chronic liver disease: effects of rifaximin on platelet count. | The American journal of gastroenterology 20101201 |
| Rifaximin for the treatment of hepatic encephalopathy. | Transplantation proceedings 20101201 |
| Rifaximin (Xifaxan 550) for hepatic encephalopathy. | The Medical letter on drugs and therapeutics 20101101 |
| [Effectiveness confirmed in studies. Intestine selective antibiotic reduces irritable bowel syndrome effectively]. | MMW Fortschritte der Medizin 20101028 |
| Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. | The Journal of pharmacology and experimental therapeutics 20101001 |
| Drug therapy: rifaximin. | Hepatology (Baltimore, Md.) 20101001 |
| Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. | Alimentary pharmacology & therapeutics 20101001 |
| A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. | Journal of clinical gastroenterology 20100901 |
| Bile acids improve the antimicrobial effect of rifaximin. | Antimicrobial agents and chemotherapy 20100901 |
| Rifaximin in hepatic encephalopathy: more than just a non-absorbable antibiotic? | Journal of hepatology 20100901 |
| Mechanisms, diagnosis and management of hepatic encephalopathy. | Nature reviews. Gastroenterology & hepatology 20100901 |
| Cyclic antibiotic therapy for diverticular disease: a critical reappraisal. | Journal of gastrointestinal and liver diseases : JGLD 20100901 |
| Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20100801 |
| Rifaximin diminishes neutropenia following potentially lethal whole-body radiation. | Experimental biology and medicine (Maywood, N.J.) 20100701 |
| Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. | Expert review of anti-infective therapy 20100701 |
| Rifaximin treatment in hepatic encephalopathy. | The New England journal of medicine 20100624 |
| Rifaximin treatment in hepatic encephalopathy. | The New England journal of medicine 20100624 |
| Rifaximin treatment in hepatic encephalopathy. | The New England journal of medicine 20100624 |
| Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. | The Cochrane database of systematic reviews 20100616 |
| Persistent portosystemic shunts after liver transplantation causing episodic hepatic encephalopathy. | Digestive diseases and sciences 20100601 |
| Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20100601 |
| Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea. | Alimentary pharmacology & therapeutics 20100601 |
| Pharmacotherapy of hepatic encephalopathy in cirrhosis. | Expert opinion on pharmacotherapy 20100601 |
| Rifaximin for inflammatory bowel disease. | Digestive diseases and sciences 20100601 |
| [Chronic diverticular diseases. Rifaximin reduces symptoms and complications]. | MMW Fortschritte der Medizin 20100527 |
| Factors affecting compliance and persistence with treatment for hepatic encephalopathy. | Pharmacotherapy 20100501 |
| Pharmacoeconomics of hepatic encephalopathy. | Pharmacotherapy 20100501 |
| Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. | Expert review of anti-infective therapy 20100501 |
| Antibiotic therapy may improve idiopathic restless legs syndrome: prospective, open-label pilot study of rifaximin, a nonsystemic antibiotic. | Sleep medicine 20100401 |
| Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity. | Digestive diseases and sciences 20100401 |
| Rifaximin and Crohn's disease: a new solution to an old problem? | Digestive diseases and sciences 20100401 |
| In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. | Journal of clinical pathology 20100401 |
| Rifaximin treatment in hepatic encephalopathy. | The New England journal of medicine 20100325 |
| Gut flora and hepatic encephalopathy in patients with cirrhosis. | The New England journal of medicine 20100325 |
| Structural elucidation of the Rifaximin Ph. Eur. Impurity H. | Journal of pharmaceutical and biomedical analysis 20100311 |
| Review article: the modern management of hepatic encephalopathy. | Alimentary pharmacology & therapeutics 20100301 |
| Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. | International journal of antimicrobial agents 20100301 |
| Rifaximin and nonabsorbable disaccharides for hepatic encephalopathy. | European journal of gastroenterology & hepatology 20100301 |
| Stability of extemporaneously prepared rifaximin oral suspensions. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100215 |
| Bacterial diarrhea. | The New England journal of medicine 20100211 |
| Diverticular disease: what is the best long-term treatment? | Nature reviews. Gastroenterology & hepatology 20100201 |
| Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. | Current opinion in gastroenterology 20100101 |
| Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. | Journal of clinical gastroenterology 20100101 |
| Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. | Journal of travel medicine 20100101 |
| [Efficacy of rifaksimin in excessive bacterial growth syndrome after cholecystectomy]. | Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20100101 |
| A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rifaximin for the prevention of travelers' diarrhea in US military personnel deployed to Incirlik Air Base, Incirlik, Turkey. | Journal of travel medicine 20100101 |
| Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. | Anaerobe 20091201 |
| Rifaximin in the management of colonic diverticular disease. | Expert review of gastroenterology & hepatology 20091201 |
| On-line 2D-LC-ESI/MS/MS determination of rifaximin in rat serum. | Biomedical chromatography : BMC 20091101 |
| Alcoholic hepatitis. | The New England journal of medicine 20091008 |
| Use and safety of rifaximin in children with inflammatory bowel disease. | Journal of pediatric gastroenterology and nutrition 20091001 |
| Review article: the current and evolving treatment of colonic diverticular disease. | Alimentary pharmacology & therapeutics 20090915 |
| A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. | The American journal of gastroenterology 20090901 |
| IgE-mediated reactions to rifaximin and rifamycin SV and cross-reactivity among rifamycins. | Allergy 20090801 |
| Hepatic encephalopathy: pathophysiology and emerging therapies. | The Medical clinics of North America 20090701 |
| FPIN's Clinical Inquiries: Effective management of flatulence. | American family physician 20090615 |
| Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. | World journal of gastroenterology 20090607 |
| Rapid determination of rifaximin in rat serum and urine by direct injection on to a shielded hydrophobic stationary phase by HPLC. | Biomedical chromatography : BMC 20090601 |
| Rifaximin pharmacology and clinical implications. | Expert opinion on drug metabolism & toxicology 20090601 |
| [Evidence-based therapy of irritable bowel syndrome. Intestine selective antibiotic relieves symptoms significantly]. | MMW Fortschritte der Medizin 20090521 |
| Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. | Alimentary pharmacology & therapeutics 20090501 |
| Treatment of cryptosporidiosis. | Expert review of anti-infective therapy 20090501 |
| Immunoregulatory activity of rifaximin associated with a resistant mutant of Bifidobacterium infantis. | International journal of antimicrobial agents 20090401 |
| Review of rifaximin as treatment for SIBO and IBS. | Expert opinion on investigational drugs 20090301 |
| Mesalazine and rifaximin in symptomatic uncomplicated diverticular disease. | The American journal of gastroenterology 20090201 |
| Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. | Journal of clinical gastroenterology 20090101 |
| Involvement of central immunity in uncomplicated diverticular disease. | Scandinavian journal of gastroenterology 20090101 |
| Faecal calprotectin in colonic diverticular disease: a case-control study. | International journal of colorectal disease 20090101 |
| Rifaximin for treatment of hepatic encephalopathy. | The Annals of pharmacotherapy 20090101 |
| Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. | European review for medical and pharmacological sciences 20090101 |
| Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. | Journal of clinical gastroenterology 20090101 |
| [Evaluation of alpha-normiks (rifaximin) efficacy in the treatment of patients with diverticular disease associated with medium and severe intestinal dysbacteriosis]. | Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20090101 |
| The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. | Therapeutics and clinical risk management 20090101 |
| [Rifaksimin in complex treatment of Helicobacter pylori infection in children (a pilot study)]. | Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20090101 |
| [Bacterially induced traveler's diarrhea. Local antibiosis effective without systemic effects]. | MMW Fortschritte der Medizin 20081106 |
| Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. | European journal of gastroenterology & hepatology 20081101 |
| Rifaximin for the treatment of hepatic encephalopathy. | Pharmacotherapy 20080801 |
| Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series. | The American journal of gastroenterology 20080801 |
| Small intestinal bacterial overgrowth recurrence after antibiotic therapy. | The American journal of gastroenterology 20080801 |
| Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20080701 |
| Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS. | Journal of acquired immune deficiency syndromes (1999) 20080701 |
| Molecular and phenotypic traits of in-vitro-selected mutants of Bifidobacterium resistant to rifaximin. | International journal of antimicrobial agents 20080601 |
| Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms. | Digestive diseases and sciences 20080501 |
| Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy. | Digestive diseases and sciences 20080501 |
| Systematic review: prevention of travellers' diarrhoea. | Alimentary pharmacology & therapeutics 20080501 |
| Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. | The Journal of antimicrobial chemotherapy 20080501 |
| Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication. | The American journal of gastroenterology 20080501 |
| Rifaximin for the treatment of hepatic encephalopathy. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080501 |
| Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. | Journal of chemotherapy (Florence, Italy) 20080401 |
| Rifaximin treatment for symptoms of irritable bowel syndrome. | The Annals of pharmacotherapy 20080301 |
| Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. | Digestive diseases and sciences 20080101 |
| 'Ecologic niche' therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy. | The American journal of gastroenterology 20080101 |
| Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. | BMC gastroenterology 20080101 |
| In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. | Diagnostic microbiology and infectious disease 20071201 |
| Microbial host interactions in IBD: implications for pathogenesis and therapy. | Current gastroenterology reports 20071201 |
| Association between hypothyroidism and small intestinal bacterial overgrowth. | The Journal of clinical endocrinology and metabolism 20071101 |
| The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. | Alimentary pharmacology & therapeutics 20071015 |
| Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. | Inflammatory bowel diseases 20071001 |
| The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. | Pharmacotherapy 20071001 |
| Rifaximin is a gut-specific human pregnane X receptor activator. | The Journal of pharmacology and experimental therapeutics 20070701 |
| Part XI. Trimethoprim-sulfamethoxazole, nitrofurantoin, chloramphenicol, metronidazole and tinidazole, rifaximin, and nitazoxanide. | The Journal of the Oklahoma State Medical Association 20070701 |
| Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. | Alimentary pharmacology & therapeutics 20070601 |
| Sensitive quantification of rifaximin in human plasma by liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501 |
| Genetic and proteomic characterization of rifaximin resistance in Bifidobacterium infantis BI07. | Research in microbiology 20070501 |
| Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. | The American journal of the medical sciences 20070501 |
| Interaction between rifaximin and dietary fibre in patients with diverticular disease. | Alimentary pharmacology & therapeutics 20070401 |
| High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. | Alimentary pharmacology & therapeutics 20070401 |
| Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20070401 |
| Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070315 |
| Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. | Digestive diseases and sciences 20070301 |
| Can we ignore minimal hepatic encephalopathy any longer? | Hepatology (Baltimore, Md.) 20070301 |
| Antibiotic may improve irritable bowel syndrome. | Mayo Clinic health letter (English ed.) 20070301 |
| Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. | The Annals of pharmacotherapy 20070201 |
| Review article: the current pharmacological therapies for hepatic encephalopathy. | Alimentary pharmacology & therapeutics 20070201 |
| Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. | World journal of gastroenterology 20070114 |
| Treatment of patients with irritable bowel syndrome. | American family physician 20070101 |
| Rifaximin treatment of pathogen-negative travelers' diarrhea. | Journal of travel medicine 20070101 |
| Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? | Digestive diseases (Basel, Switzerland) 20070101 |
| Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. | Journal of clinical gastroenterology 20070101 |
| Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. | Advances in medical sciences 20070101 |
| Emerging therapies in the treatment of Clostridium difficile-associated disease. | The Annals of pharmacotherapy 20061201 |
| Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. | Transplantation proceedings 20061201 |
| Targeting intestinal microflora in inflammatory bowel disease. | World journal of gastroenterology 20061128 |
| [Significance of gastrointestinal antibiotics in gastrointestinal diseases: Normix, the non-absorbable antibiotic]. | Orvosi hetilap 20061022 |
| Summaries for patients. Can antibiotics improve the symptoms of the irritable bowel syndrome? | Annals of internal medicine 20061017 |
| The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. | Annals of internal medicine 20061017 |
| Rifaximin: an alternative for the treatment of hepatic encephalopathy. | Connecticut medicine 20060901 |
| Role of gut microflora and probiotic effects in the irritable bowel syndrome. | Acta bio-medica : Atenei Parmensis 20060801 |
| A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. | The American journal of tropical medicine and hygiene 20060601 |
| Current and future developments in travelers' diarrhea therapy. | Expert review of anti-infective therapy 20060601 |
| Review article: uncomplicated diverticular disease of the colon. | Alimentary pharmacology & therapeutics 20060515 |
| Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060501 |
| Prevention of first overt episode of hepatic encephalopathy after TIPS: no easy task. | Hepatology (Baltimore, Md.) 20060501 |
| What's new in clinical pharmacology and therapeutics. | WMJ : official publication of the State Medical Society of Wisconsin 20060501 |
| Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. | Alimentary pharmacology & therapeutics 20060415 |
| Rifaximin for active ulcerative colitis. | Inflammatory bowel diseases 20060401 |
| Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. | Minerva gastroenterologica e dietologica 20060301 |
| Transient lactose malabsorption in patients affected by symptomatic uncomplicated diverticular disease of the colon. | Digestive diseases and sciences 20060301 |
| [Modern indications on the medical treatment of symptomatic diverticular disease]. | Il Giornale di chirurgia 20060301 |
| Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060215 |
| A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. | The American journal of gastroenterology 20060201 |
| Germs, gas and the gut; the evolving role of the enteric flora in IBS. | The American journal of gastroenterology 20060201 |
| [The use of Rifaximin in daily clinical practice]. | Orvosi hetilap 20060122 |
| [Diverticulosis/diverticulitis? What are conservative therapy possibilities?]. | Medizinische Klinik (Munich, Germany : 1983) 20060115 |
| Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. | Digestion 20060101 |
| Management of hepatic encephalopathy: focus on antibiotic therapy. | Digestion 20060101 |
| Eradication of Helicobacter pylori: are rifaximin-based regimens effective? | Digestion 20060101 |
| Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea. | Drug safety 20060101 |
| Travellers' diarrhoea: contemporary approaches to therapy and prevention. | Drugs 20060101 |
| Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. | Digestive diseases (Basel, Switzerland) 20060101 |
| Rifaximin (Xifaxan) for traveler's diarrhea. | American family physician 20051215 |
| Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment. | Current opinion in infectious diseases 20051201 |
| Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051201 |
| Colonic diverticular disease. | Clinical evidence 20051201 |
| Rifaximin--the promising anti-microbial for enteric infections. | The Journal of infection 20051001 |
| A dance teacher with kidney-pancreas transplant and diarrhoea: what is the cause? | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050801 |
| An open-label evaluation of rifaximin in the treatment of active Crohn's disease. | Current medical research and opinion 20050801 |
| Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. | Alimentary pharmacology & therapeutics 20050701 |
| Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. | Yonsei medical journal 20050630 |
| Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study. | Alimentary pharmacology & therapeutics 20050601 |
| Summaries for patients. Can a new antibiotic safely prevent travelers' diarrhea? | Annals of internal medicine 20050517 |
| A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. | Annals of internal medicine 20050517 |
| How to hit the runs for fifty million travelers at risk. | Annals of internal medicine 20050517 |
| Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. | Journal of hepatology 20050501 |
| Rifaximin in patients with lactose intolerance. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20050501 |
| Absorbable vs. non-absorbable antibiotics in the treatment of small intestine bacterial overgrowth in patients with blind-loop syndrome. | Alimentary pharmacology & therapeutics 20050415 |
| Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. | Expert review of anti-infective therapy 20050401 |
| Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. | Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20050301 |
| Efficacy of mesalazine in the treatment of symptomatic diverticular disease. | Digestive diseases and sciences 20050301 |
| Rifaximin: a new treatment for travelers' diarrhea. | The Annals of pharmacotherapy 20050201 |
| Rifaximin--a novel antimicrobial for enteric infections. | The Journal of infection 20050201 |
| 2004 drug approval highlights: FDA update. | The Nurse practitioner 20050201 |
| Mesalazine for diverticular disease of the colon--a new role for an old drug. | Expert opinion on pharmacotherapy 20050101 |
| Rifaximin: a nonabsorbed oral antibiotic. | Reviews in gastroenterological disorders 20050101 |
| Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. | Chemotherapy 20050101 |
| Rifaximin: in vitro and in vivo antibacterial activity--a review. | Chemotherapy 20050101 |
| Rifaximin in the treatment of infectious diarrhea. | Chemotherapy 20050101 |
| Management of hepatic encephalopathy: role of rifaximin. | Chemotherapy 20050101 |
| Management of inflammatory bowel disease: does rifaximin offer any promise? | Chemotherapy 20050101 |
| Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin. | Chemotherapy 20050101 |
| Management of diverticular disease: is there room for rifaximin? | Chemotherapy 20050101 |
| Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract. | Chemotherapy 20050101 |
| Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. | Reviews in gastroenterological disorders 20050101 |
| Rifaximin: a review of its use in the management of traveller's diarrhoea. | Drugs 20050101 |
| Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study. | Drugs under experimental and clinical research 20050101 |
| Colonic diverticular disease. | Clinical evidence 20041201 |
| Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20041101 |
| [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders]. | Orvosi hetilap 20041024 |
| Rifaximin (Xifaxan) for travelers' diarrhea. | The Medical letter on drugs and therapeutics 20040913 |
| New drugs and dosage forms. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040715 |
| [Rifaximin]. | Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20040601 |
| Colonic diverticular disease. | Clinical evidence 20040601 |
| Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension. | Minerva gastroenterologica e dietologica 20040601 |
| Solution structure of rifaximin and its synthetic derivative rifaximin OR determined by experimental NMR and theoretical simulation methods. | Bioorganic & medicinal chemistry 20040501 |
| Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. | Medical science monitor : international medical journal of experimental and clinical research 20040501 |
| CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. | International journal of colorectal disease 20040301 |
| Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20040201 |
| [Evaluation of Helicobacter pylori susceptibility to rifaximin]. | Gastroenterologia y hepatologia 20040101 |
| Does rifaximin prevent complications of diverticular disease? A retrospective study. | European review for medical and pharmacological sciences 20040101 |
| Susceptibility to rifaximin of Vibrio cholerae strains from different geographical areas. | The Journal of antimicrobial chemotherapy 20030801 |
| Colonic diverticular disease. | Clinical evidence 20030601 |
| Therapy of travelers' diarrhea with rifaximin on various continents. | The American journal of gastroenterology 20030501 |
| Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. | International journal of colorectal disease 20030101 |
| Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. | Journal of hepatology 20030101 |
| Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20020701 |
| Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. | Journal of chemotherapy (Florence, Italy) 20020601 |
| [Rifaximin in the treatment of hepatic encephalopathy]. | Vnitrni lekarstvi 20020601 |
| Colonic diverticular disease. | Clinical evidence 20020601 |
| Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. | Hepato-gastroenterology 20020101 |
| Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. | Digestion 20020101 |
| Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011201 |
| Rifaximin: a new approach to the treatment of travelers' diarrhea. Introduction. | Journal of travel medicine 20011201 |
| Treatment of travelers' diarrhea. | Journal of travel medicine 20011201 |
| Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea. | Journal of travel medicine 20011201 |
| Rifaximin: a new approach to the treatment of travelers' diarrhea. Conclusion. | Journal of travel medicine 20011201 |
| Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats. | Pharmacological research 20011101 |
| Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | Immunopharmacology and immunotoxicology 20011101 |
| [Role of prebiotics and probiotics in therapeutic management of cryptogenetic inflammatory bowel disease]. | Gastroenterologie clinique et biologique 20010901 |
| In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. | The Journal of antimicrobial chemotherapy 20010601 |
| Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. | Drugs 19950301 |
Related Products
© 2019 Angene International Limited. All rights Reserved.